Lentiviruses are quite effective gene delivery systems for stable production of genetically engineered human cells. However, prior to using lentivirus to deliver genetic materials to cells of interest, the normal course of production of these lentiviruses involves a lengthy collection, purification, preservation, and quantification process. In this report, we demonstrate the ability for producer HEK293T cells to simultaneously produce lentiviral particles and transduce (i.e., infect) target cells through a membrane-based coculture system in a continuous, real-time mode which negates the need for a separate viral collection and quantification process. The coculture system was evaluated for major design features such as variations in HEK293T seeding density, target cell type densities, as well as membrane porosities to identify key relationships between lentiviral particle production rate and infection kinetics for adherent and suspension cell types. As a proof-of-concept for the creation of an engineered cell immunotherapy, we describe the ability to engineer human T cells isolated from PBMCs under the control of this coculture system in under 6 days with a GFP construct. These studies suggest the capability to combine and more closely automate the transfection/transduction process in order to facilitate well-timed and cost-effective transduction of target cell types. These experiments provide novel insight into the forthcoming transition into improved manufacturing systems for viral production and subsequent cell engineering.
Keywords: Engineered cell therapy; Lentivirus transduction; Scalable engineering systems.
Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles.J Vis Exp. 2012 Apr 8;(62):e3171. doi: 10.3791/3171. J Vis Exp. 2012. PMID: 22508377 Free PMC article.
Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide.Blood. 2002 Apr 1;99(7):2342-50. doi: 10.1182/blood.v99.7.2342. Blood. 2002. PMID: 11895766
Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines.Hum Gene Ther Methods. 2017 Dec;28(6):330-339. doi: 10.1089/hgtb.2017.086. Epub 2017 Nov 21. Hum Gene Ther Methods. 2017. PMID: 28826344 Free PMC article.
Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles.Metab Eng. 2005 Sep-Nov;7(5-6):426-36. doi: 10.1016/j.ymben.2005.06.006. Epub 2005 Aug 15. Metab Eng. 2005. PMID: 16102993
Challenges of up-scaling lentivirus production and processing.J Biotechnol. 2016 Dec 20;240:23-30. doi: 10.1016/j.jbiotec.2016.10.016. Epub 2016 Oct 18. J Biotechnol. 2016. PMID: 27769802 Review.